Janux的肿瘤激活平台吸引BMS达成潜在8.5亿美元交易
Janux’s tumor-activated platform draws BMS in potential $850M deal
生物技术与制药领域的最新动态
Janux’s tumor-activated platform draws BMS in potential $850M deal
Appointments and advancements for Jan. 22, 2026
Financings for Jan. 22, 2026
Other news to note for Jan. 22, 2026
Regulatory actions for Jan. 22, 2026
Corcept’s relacorilant could reach $2.1B ovarian cancer market
Rezubio Pharmaceuticals discloses new drug conjugates to treat fibrosis
Lunan New Time Biotechnical reports new camptothecin derivatives and their ADCs
Shanghai Qingrun Pharmaceutical Technology synthesizes new GTPase KRAS mutant inhibitors
Beyang Therapeutics discovers salts of VEGFR inhibitors
Sunshine Lake Pharma divulges new PKMYT1 inhibitors
Appointments and advancements for Jan. 21, 2026
Financings for Jan. 21, 2026
In the clinic for Jan. 21, 2026
Other news to note for Jan. 21, 2026
Regulatory actions for Jan. 21, 2026
Korean universities patent new PAK4 degradation inducers
Novacell Technology reports new FPR2 agonists
Nippon Zoki Pharmaceutical synthesizes new GABA-A receptor subunit positive allosteric modulators
Novartis discovers new CDK inhibitors